Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ifosfamide combination chemotherapy for advanced gynecologic malignancies].

X Li1, L Liu, L Wu

  • 1Cancer Institute (Hospital), Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|January 10, 2002
PubMed
Summary

Ifosfamide (IFO) combination chemotherapy shows effectiveness in advanced gynecologic cancers, particularly platinum-sensitive ovarian cancers. However, severe myelosuppression necessitates careful monitoring due to prior intensive treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nuclear transfer in sheep embryos: the effect of cell-cycle coordination between nucleus and cytoplasm and the use of in vitro matured oocytes.

Molecular reproduction and development·1997
Same author

Role of secreted proteins and gonadotrophins in promoting full maturation of porcine oocytes in vitro.

Molecular reproduction and development·1997
Same author

The responses of rat trigeminal ganglion neurons to capsaicin and two nonpungent vanilloid receptor agonists, olvanil and glyceryl nonamide.

The Journal of neuroscience : the official journal of the Society for Neuroscience·1997
Same author

Localization of human intestinal defensin 5 in Paneth cell granules.

Infection and immunity·1997
Same author

Evidence for the existence of two ATP-sensitive Rb+ occlusion pockets within the transmembrane domains of Na+/K+-ATPase.

The Journal of biological chemistry·1997
Same author

Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.

Genes, chromosomes & cancer·1997

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Medical Chemotherapy

Background:

  • Advanced gynecologic malignancies pose significant treatment challenges.
  • Recurrent or refractory cases often require novel therapeutic strategies.
  • Evaluating chemotherapy efficacy in heavily pre-treated patients is crucial.

Purpose of the Study:

  • To assess the clinical effectiveness and toxicity of ifosfamide (IFO) based combination chemotherapy.
  • To determine response rates in patients with advanced gynecologic cancers.
  • To identify specific patient subgroups who may benefit most from IFO therapy.

Main Methods:

  • A cohort of 34 patients with advanced gynecologic malignancies was treated.
  • 26 ovarian cancer patients received the IEP regimen (Ifosfamide, VP16, PDD).

Related Experiment Videos

  • 8 patients with uterine sarcoma, cervical, or endometrial cancer received IFO combination chemotherapy.

    • Main Results:

    • An overall response rate of 35.3% was observed, with 8.8% complete responses.
    • Ovarian cancer patients showed a 30.8% response rate.
    • Severe hematological toxicity, including leucopoenia and thrombocytopenia, was noted, with two treatment-related deaths.

    Conclusions:

    • Ifosfamide combination chemotherapy is a viable option for recurrent or progressive gynecologic malignancies.
    • Platinum-sensitive tumors demonstrated better response rates.
    • Significant myelosuppression is a major toxicity concern, likely exacerbated by prior chemotherapy.